Different experimental models have substantially established that the anti-angiogenic (AAG) group of drugs are able to control the growth of tumor mass by cutting down the nutritive supply to the cancer cells. The mechanism of action of this group of drugs acts on the cells of the vascular endothelium. Recently, different AAG drugs have been in clinical trials. Initial clinical trials showed that application of AAG drugs produced different sorts of toxicity in patients, so calibration of the doses and drug application schedules are very important at present. Hence, development of analytical models would definitely help in this respect, particularly at the individual level. The analytical model presented here may help to make a judicious choice of drug doses and drug schedule to control the growth of the tumor system under the condition of malignancy.